• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Marpai Inc. (Amendment)

    11/22/23 9:45:27 PM ET
    $MRAI
    Misc Health and Biotechnology Services
    Health Care
    Get the next $MRAI alert in real time by email
    SC 13D/A 1 copy_of_yaron_13d.htm SC 13D/A SC 13D/A

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549 SCHEDULE 13D

    (Amendment No. 1)

    Under the Securities Exchange Act of 1934

     

    MARPAI, INC.

     

    (Name of Issuer)

     

    Class A Common Stock, $0.0001 par value (Title of Class of Securities)

     

    571354 109

     

    (CUSIP Number)

     

    Yaron Eitan c/o Marpai, Inc.

    615 Channelside Drive, Suite 207

    Tampa, Florida 33602

    (646) 303-3483

     

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    November 17, 2023

     

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7(b) for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     


     

     

     

     

     

    SCHEDULE 13D

     

    CUSIP No. 571354 109

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Yaron Eitan

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)
    x
    (b)

    3

    SEC USE ONLY

    4

    SOURCE OF FUNDS (See Instructions)

     

    PF

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

    o

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Dual Citizenship: United States citizen and Israeli citizen

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

    WITH

    7

    SOLE VOTING POWER 460,902(1)

    8

    SHARED VOTING POWER 1,956,631(2)

    9

    SOLE DISPOSITIVE POWER 460,902(1)

    10

    SHARED DISPOSITIVE POWER 1,956,631

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,471,535(1)

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

    o

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.9%(3)

    14

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN

     

    (1)
    Comprised of (i) 460,902 shares of the Class A common stock, par value $0.0001 per share (the “Common Stock”) of Marpai, Inc. (the “Issuer”) held directly by Yaron Eitan, (ii) 56,948 shares of Common Stock issuable upon the exercise of warrants at an exercise price of $31.60 per share expiring on February 9, 2026 (the “Warrants”), and (iii) 62,500 options to purchase 62,500 shares of Common Stock (the “Options”).

     

    (2)
    Pursuant to the Agreement Relating to Voting Power between Co-Founders of Marpai, Inc. and Grant of a Power of Attorney

     


     

    and Proxy, dated June 28, 2021 (the "Power of Attorney and Proxy"), (i) HillCour Investment Fund, LLC and WellEnterprises USA, LLC (together, the "HillCour Founding Group") and (ii) Eli David, Yaron Eitan, Edmundo Gonzalez and Grays West Ventures, LLC (collectively, the "Grays Founding Group"), share voting power over a total of 1,956,633 shares of Common Stock (the “Proxy

    Shares”) with respect to certain specified matters described below. As a result of the Power of Attorney and Proxy, the HillCour Founding Group and Grays Founding Group, of which Yaron Eitan is a member, are deemed to be a "group" under Rule 13d-5(d) of the Act.

     

    The matters with respect to which such voting power is shared are: (i) any change to the composition of the Issuer’s Board of Directors, provided that all Proxy Shares shall be voted for the election of Damien Francis Lamendola (or another nominee of the HillCour Founding Group) as a director of the Issuer (as well as against any proposal to remove Damien Francis Lamendola (or such other nominee) as a director of the Issuer); (ii) the sale of all or substantially all of the assets of the Issuer, the sale of all or substantially all of the capital stock of the Issuer, or a merger involving the Issuer; (iii) the replacement of the Chief Executive Officer or other C-level officers of the Issuer; (iv) the amending the corporate documents of the Issuer or otherwise approving any agreement, document or instrument in connection with fundraising of any type or structure for the Issuer; (v) approval of the Issuer’s annual budget and business plan; and (vi) the Issuer’s acquisition of any business or entity or the entry into a joint venture or other collaborative agreement with a potential target business, assets, entity, or partner.

     

    (3)
    Percentage is calculated based on 7,810,621 shares of Common Stock outstanding as of November 22, 2023.

     

    This Amendment No. 1 to Schedule 13D (this “Schedule 13D/A”) amends and supplements the Schedule 13D initially filed with the Securities and Exchange Commission (the “SEC”) on December 21, 2021, by Yaron Eitan (the “Reporting Person”), pursuant to Rule 13d-1(e) under the Act.

     

    Item 3. Source and Amount of Funds or Other Considerations

     

    Yaron Eitan expended an aggregate of approximately $123,000 of his own investment capital to acquire 100,000 shares of Common Stock the Issuer disclosed in this Schedule 13D/A.

    Item 4. Purpose of Transaction

     

    Yaron Eitan acquired the securities for business investment purposes.

     

    Item 5. Interest in Securities of the Issuer

     

    (a) As of November 22, 2023, Yaron Eitan directly beneficially owned 460,902 shares of the Issuer’s Common Stock which are comprised of 341,454 shares of Common Stock, 56,948 Warrants to purchase 56,948 shares of Common Stock, and 62,500 Options to purchase 62,500 shares of Common Stock.

     

    Pursuant to the Agreement Relating to Voting Power between Co-Founders of Marpai, Inc. and the Power of Attorney and Proxy, HillCour Founding Group and Grays Founding Group, share voting power over a total of 1,956,633 shares of the Issuer’s Common Stock with respect to certain specified matters described below. As a result of the Power of Attorney and Proxy, the HillCour Founding Group and Grays Founding Group, of which Yaron Eitan is a member, are deemed to be a "group" under Rule 13d-5(d) of the Act.

     

    The matters with respect to which such voting power is shared are: (i) any change to the composition of the Issuer’s Board of Directors, provided that all Proxy Shares shall be voted for the election of Damien Francis Lamendola (or another nominee of the HillCour Founding Group) as a director of the Issuer (as well as against any proposal to remove Damien Francis Lamendola (or such other nominee) as a director of the Issuer); (ii) the sale of all or substantially all of the assets of the Issuer, the sale of all or substantially all of the capital stock of the Issuer, or a merger involving the Issuer; (iii) the replacement of the Chief Executive Officer or other C-level officers of the Issuer; (iv) amending the corporate documents of the Issuer or otherwise approving any agreement, document or instrument in connection with fundraising of any type or structure for the Issuer; (v) approval of the Issuer’s annual budget and business plan; and (vi) the Issuer’s acquisition of any business or entity or the entry into a joint venture or other collaborative agreement with a potential target business, assets, entity, or partner. These securities represent approximately 33.8% of the shares of Issuer’s Common Stock of the Issuer.

     

    (b) Yaron Eitan has sole voting and dispositive power of 460,902 shares of Common Stock of the Issuer, and 1,956,633 shares of

    Common Stock held by HillCour Founding Group and Grays Founding Group, over which Yaron Eitan has voting and dispositive

    power, as of November 22, 2023.

     

    (c)
    Not applicable.

     

    (d)
    Not applicable.

     


     

     

    (e)
    Not applicable.

     

     

     

     

     


     

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated : November 22, 2023

     

     

     

    By: /s/ Yaron Eitan

    Yaron Eitan

     

     

     

     

     

     


    Get the next $MRAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRAI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MRAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MARPAI REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      Marpai's turnaround momentum is building TAMPA, Fla., May 14, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced financial results for the first quarter of 2025. The Company expects to hold a webcast to discuss the results on May 15, 2025. Marpai CEO Damien Lamendola commented, "Our consistent double-digit success in cutting operating expenses and improving our bottom line signals what we believe is a critical inflection point for the Company. Looking ahead to the second quarter, we are focused on completing several key initiatives, including the launch of our Health

      5/14/25 4:07:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • MARPAI HIRES DALLAS SCRIP AS CHIEF OPERATING OFFICER

      Marpai Bolsters Leadership Team to Drive Profitable High-Growth Strategy with Key Executive Appointment  TAMPA, Fla., May 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced a significant addition to its leadership team with the appointment of Dallas Scrip as Chief Operating Officer (COO) and President of MarpaiRx. This strategic hire underscores Marpai's commitment to accelerating profitable growth and enhancing operational excellence within the dynamic healthcare landscape. Prior to joining Marpai, Mr. Scrip demonstrated significant success in startup, ear

      5/13/25 9:01:00 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • MARPAI TO HOST WEBCAST ON MAY 15, 2025 TO DISCUSS FIRST QUARTER 2025 FINANCIAL RESULTS

      TAMPA, Fla., May 7, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services. The Company will host a conference call and webcast on Thursday, May 15 at 8:30 a.m. ET to present the Company's operational and financial highlights for Q1 2025. The Company will report its first quarter 2025 results on Wednesday after the market close. Event: Marpai 2025 Q1 Financial Results Conference Call Date: May 15, 2025 Time: 8:30 a.m. Eastern Time Call:    US: 1-646-357-8785 / Toll Free: 1-800-836-8184 Webcast:    https://app.webinar.net/e6RGaxOgz3n Follow us on X.com and LinkedIn You may stream th

      5/7/25 4:03:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Marpai Inc.

      SC 13D/A - Marpai, Inc. (0001844392) (Subject)

      12/9/24 5:14:07 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Marpai Inc.

      SC 13D/A - Marpai, Inc. (0001844392) (Subject)

      9/4/24 7:55:41 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13D/A filed by Marpai Inc. (Amendment)

      SC 13D/A - Marpai, Inc. (0001844392) (Subject)

      5/29/24 4:01:02 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Lamendola Damien was granted 600,000 shares (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      1/29/25 4:01:10 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • New insider Intelligent Fanatics Capital Management Llc claimed ownership of 3,729,414 shares (SEC Form 3)

      3 - Marpai, Inc. (0001844392) (Issuer)

      1/2/25 9:41:02 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • President and COO Powers John Paul was granted 100,000 shares and bought $11,300 worth of shares (10,000 units at $1.13), increasing direct ownership by 73% to 260,000 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:15:20 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and COO Powers John Paul was granted 100,000 shares and bought $11,300 worth of shares (10,000 units at $1.13), increasing direct ownership by 73% to 260,000 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:15:20 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Chief Financial Officer Johnson Steve Andrew was granted 100,000 shares and bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 29% to 473,061 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:14:54 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Director Eitan Yaron was granted 5,000 shares and bought $124,999 worth of shares (110,619 units at $1.13), increasing direct ownership by 17% to 789,073 units (SEC Form 4)

      4 - Marpai, Inc. (0001844392) (Issuer)

      12/9/24 5:14:32 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    Leadership Updates

    Live Leadership Updates

    See more
    • MARPAI HIRES DALLAS SCRIP AS CHIEF OPERATING OFFICER

      Marpai Bolsters Leadership Team to Drive Profitable High-Growth Strategy with Key Executive Appointment  TAMPA, Fla., May 13, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced a significant addition to its leadership team with the appointment of Dallas Scrip as Chief Operating Officer (COO) and President of MarpaiRx. This strategic hire underscores Marpai's commitment to accelerating profitable growth and enhancing operational excellence within the dynamic healthcare landscape. Prior to joining Marpai, Mr. Scrip demonstrated significant success in startup, ear

      5/13/25 9:01:00 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Health In Tech Announces Innovative Collaboration with MARPAI and Vitable DPC to Offer Competitive Quotes in Enhanced Self-Funded Solutions

      STUART, Fla., Jan. 22, 2025 /PRNewswire/ -- Health In Tech, an Insurtech platform company backed by third-party AI technology, is thrilled to announce a new strategic collaboration with Vitable and MARPAI. This collaboration aims to introduce a  competitively priced self-funded health plan to the market. By utilizing the strength of Vitable's Direct Primary Care (DPC), a health plan, and stop-loss coverage, Health In Tech seeks to offer low quotes on their eDIYBS platform, and to set an ambitious standard in affordability and efficiency. Vitable's enhanced primary care plan co

      1/22/25 5:00:00 PM ET
      $HIT
      $MRAI
      Specialty Insurers
      Finance
      Misc Health and Biotechnology Services
      Health Care
    • George Economou Files Definitive Proxy Statement and Sends Letter to Genco Shareholders

      Highlights Urgent Need for An Independent Director Perspective to Address Genco's Persistent Underperformance and Unlock Value for Shareholders Outlines Concerns with Chairman James Dolphin's Outsized Influence in the Genco Boardroom Urges Shareholders to Vote FOR the Election of GK Investor Nominee Robert Pons on the BLUE Universal Proxy Card and WITHHOLD on Genco Board Chairman James Dolphin GK Investor LLC ("GK"), an affiliate of George Economou that is an approximately 5.3% shareholder of Genco Shipping & Trading Limited ("Genco" or the "Company") (NYSE:GNK), today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connec

      4/18/24 1:07:00 PM ET
      $GNK
      $INSG
      $MRAI
      $SEAC
      Marine Transportation
      Consumer Discretionary
      Telecommunications Equipment
      Telecommunications

    $MRAI
    Financials

    Live finance-specific insights

    See more
    • MARPAI REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

      Marpai's turnaround momentum is building TAMPA, Fla., May 14, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced financial results for the first quarter of 2025. The Company expects to hold a webcast to discuss the results on May 15, 2025. Marpai CEO Damien Lamendola commented, "Our consistent double-digit success in cutting operating expenses and improving our bottom line signals what we believe is a critical inflection point for the Company. Looking ahead to the second quarter, we are focused on completing several key initiatives, including the launch of our Health

      5/14/25 4:07:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • MARPAI TO HOST WEBCAST ON MAY 15, 2025 TO DISCUSS FIRST QUARTER 2025 FINANCIAL RESULTS

      TAMPA, Fla., May 7, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services. The Company will host a conference call and webcast on Thursday, May 15 at 8:30 a.m. ET to present the Company's operational and financial highlights for Q1 2025. The Company will report its first quarter 2025 results on Wednesday after the market close. Event: Marpai 2025 Q1 Financial Results Conference Call Date: May 15, 2025 Time: 8:30 a.m. Eastern Time Call:    US: 1-646-357-8785 / Toll Free: 1-800-836-8184 Webcast:    https://app.webinar.net/e6RGaxOgz3n Follow us on X.com and LinkedIn You may stream th

      5/7/25 4:03:00 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • MARPAI TO HOST WEBCAST ON MARCH 27, 2025 TO DISCUSS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

      TAMPA, Fla., March 20, 2025 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (OTCQX:MRAI), a technology platform company, operates as a national Third-Party Administrator (TPA) through its subsidiaries. We're transforming the $22 billion TPA market by offering affordable, intelligent, healthcare solutions to self-funded employer health plans. The Company will host a conference call and webcast on Thursday, March 27 at 8:30 a.m. ET to present the Company's operational and financial highlights for 2024. The Company will report its fourth quarter and full year 2024 results on Wednesday after the market close. Event: Marpai 2024 Financial Results Conference Call Date: March 27, 2025 Time

      3/20/25 8:32:00 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care

    $MRAI
    SEC Filings

    See more
    • SEC Form 10-Q filed by Marpai Inc.

      10-Q - Marpai, Inc. (0001844392) (Filer)

      5/14/25 4:20:40 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Marpai Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Marpai, Inc. (0001844392) (Filer)

      5/14/25 4:15:36 PM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care
    • Marpai Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Marpai, Inc. (0001844392) (Filer)

      5/13/25 9:23:22 AM ET
      $MRAI
      Misc Health and Biotechnology Services
      Health Care